# Paroxysmal Nocturnal Hemoglobinuria FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/paroxysmal-nocturnal-hemoglobinuria

> 8 upcoming FDA catalysts in paroxysmal Nocturnal Hemoglobinuria: oms906 study drug (OMER) on December 2026 (primary completion); oms906 study drug (OMER) on Dec 2026 to Mar 2027 (topline data readout); FABHALTA® (iptacopan, NVS) on Oct 2027 to Jan 2028 (topline data readout); FABHALTA® (iptacopan, NVS) on October 2027 (primary completion); and 4 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Aug to Nov 2026 | [Voydeya (danicopan) topline data readout](https://sec-api.dev/pdufa/danicopan) | AZN | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT05389449 (A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-24 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05389449)) |
| August 2026 | [Voydeya (danicopan) primary completion](https://sec-api.dev/pdufa/danicopan) | AZN | Paroxysmal Nocturnal Hemoglobinuria | delayed | "NCT05389449 (A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-24 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05389449)) |
| September 28, 2026 | [Ultomiris® (ravulizumab) primary completion](https://sec-api.dev/pdufa/ravulizumab) | REGN | Paroxysmal Nocturnal Hemoglobinuria | completed | "NCT05133531 (A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05133531)) |
| Sep to Dec 2026 | [Ultomiris® (ravulizumab) topline data readout](https://sec-api.dev/pdufa/ravulizumab) | REGN | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT05133531 (A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-28 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05133531)) |
| December 2026 | [Oms906 study drug primary completion](https://sec-api.dev/pdufa/oms906-study-drug) | OMER | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT06298955 (Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Omeros Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06298955)) |
| Dec 2026 to Mar 2027 | [Oms906 study drug topline data readout](https://sec-api.dev/pdufa/oms906-study-drug) | OMER | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT06298955 (Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Omeros Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06298955)) |
| Oct 2027 to Jan 2028 | [FABHALTA® (iptacopan) topline data readout](https://sec-api.dev/pdufa/iptacopan) | NVS | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT04747613 (Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-18 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04747613)) |
| October 2027 | [FABHALTA® (iptacopan) primary completion](https://sec-api.dev/pdufa/iptacopan) | NVS | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT04747613 (Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-18 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04747613)) |
| Oct 2028 to Jan 2029 | [Pozelimab topline data readout](https://sec-api.dev/pdufa/pozelimab) | REGN | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT05744921 (A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-10 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05744921)) |
| October 2028 | [Pozelimab primary completion](https://sec-api.dev/pdufa/pozelimab) | REGN | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT05744921 (A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-10 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05744921)) |
| Jan to Apr 2030 | [Pozelimab topline data readout](https://sec-api.dev/pdufa/pozelimab) | REGN | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT07154745 (A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-18 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07154745)) |
| January 2030 | [Pozelimab primary completion](https://sec-api.dev/pdufa/pozelimab) | REGN | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT07154745 (A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-01-18 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07154745)) |

## Drugs

- [Voydeya (danicopan)](https://sec-api.dev/pdufa/danicopan) (AZN)
- [Ultomiris® (ravulizumab)](https://sec-api.dev/pdufa/ravulizumab) (AZN)
- [Oms906 study drug](https://sec-api.dev/pdufa/oms906-study-drug) (OMER)
- [FABHALTA® (iptacopan)](https://sec-api.dev/pdufa/iptacopan) (NVS)
- [Pozelimab](https://sec-api.dev/pdufa/pozelimab) (REGN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/paroxysmal-nocturnal-hemoglobinuria.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Paroxysmal Nocturnal Hemoglobinuria FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/paroxysmal-nocturnal-hemoglobinuria

```bibtex
@misc{secapidev_indications_paroxysmal_nocturnal_hemoglobinuria_20261116,
  title        = {Paroxysmal Nocturnal Hemoglobinuria FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/paroxysmal-nocturnal-hemoglobinuria}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_paroxysmal_nocturnal_hemoglobinuria_20261116","title":"Paroxysmal Nocturnal Hemoglobinuria FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/paroxysmal-nocturnal-hemoglobinuria","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
